BCCMA: Foundational Research to Act Upon and Resist Conditions Unfavorable to Bone (FRACTURE CURB): A stitch in time saves nine!
BCCMA:采取行动并抵抗对骨骼不利的条件的基础研究(骨折遏制):及时缝一针可以节省九针!
基本信息
- 批准号:10483595
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-10-01 至 2026-09-30
- 项目状态:未结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAddressAffectAgingAnabolismAnimal ModelAnxietyBiological ModelsBone DensityBone DiseasesBone RegenerationBone ResorptionBone callusBone necrosisBone structureCartilageChronicClinicalClinical ManagementCollaborationsDiagnosisDiseaseDisease modelDual-Energy X-Ray AbsorptiometryEarly DiagnosisEarly InterventionEarly treatmentEconomic BurdenElderlyEnsureEstrogen deficiencyEtiologyFemoral FracturesFinancial costFractureFrightFutureGoalsHIVHIV InfectionsHealthHealth PersonnelHealthcare SystemsHip FracturesHospitalsHumanIncidenceIndividualIntegrated Health Care SystemsInterventionJawMedicalMental DepressionModelingMorbidity - disease rateMusMusculoskeletal PainNatural regenerationOralOsteogenesisOsteoporosisOsteoporosis preventionOsteoporoticOutcome MeasurePTH geneParticipantPatientsPharmaceutical PreparationsPharmacotherapyPhasePhenotypePostmenopausal OsteoporosisPostmenopausePre-Clinical ModelPreventionPrevention approachProcessProphylactic treatmentQuality of lifeRehabilitation therapyRejuvenationReportingResearchResearch PersonnelResearch Project GrantsResistanceResortResourcesSignal PathwaySkeletonSourceTechniquesTechnologyTestingTherapeuticTimeVeteransWeight-Bearing stateWomanabsorptionantiretroviral therapybisphosphonatebonebone healthbone lossbone massbone preservationbone qualitybone repairbone turnoverchronic paincostdietary supplementsdisabilityefficacy evaluationfracture riskfragility fracturehigh riskhormonal signalsimmune reconstitutionimprovedin vitro Modelin vivoinnovationinsightmalemenmortalitymouse modelnovelnovel strategiesnovel therapeutic interventionpharmacologicpreventpsychologicresearch studyside effectskeletal disorderstandard of carestemtooltreatment effecttreatment strategy
项目摘要
Overall Research Strategy: To ensure aging Veterans remain active and mobile with as little musculoskeletal
pain as possible, new approaches to the prevention of osteoporosis and promotion of timely bone regeneration
following a fracture are necessary. This collaborative research study brings together a group of VA investigators
with diverse perspectives, insights, models, and techniques, to synergistically attack a major clinical problem
that leads to high morbidity and mortality among Veterans, a bone fracture. The overall research strategy of each
integrated project is to use pre-clinical models of a disease that either weakens bone or delays bone repair, to
investigate novel ways to utilize or enhance the ability of parathyroid hormone (PTH) to promote bone formation,
and to assess disease and treatment effects on bone in a unified, stringent manner. Already under-diagnosed
and under-treated, osteoporosis is likely to increase the number of fragility fractures being treated at VA hospitals
without novel tools for early detection and novel treatment strategies that circumvent the rare but devastating
side effects of current therapies that inhibit bone loss. Addressing this unmet clinical need, the overall aims are
to identify therapeutic strategies to improve bone health among Veterans and to enhance the bone anabolism of
PTH signaling. The collaboration will address this overarching hypothesis: health problems disproportionately
affecting Veterans activate signaling pathways that increase bone resorption, suppress bone formation, or
impede the transition of cartilage to bone in a fracture callus such that improvements in the clinical management
of osteoporosis lie in understanding how these health problems hurt bone health.
Project Research Strategy: The traditional clinical standard of care for fracture prevention, is to screen for
osteoporosis late in the course of the disease, after bone has been denuded and fracture is imminent, before
resorting to anti-osteoporotic pharmacotherapies. Such therapies however, are inefficient at regenerating lost
bone, and bone quality, an important aspect of load bearing strength, often remains deficient. Thus, the clinical
standard of care is frequently inadequate and many patients ultimately go on to sustain a fracture, irrespective
of therapy. Compounding the problem, anti-resorptives (especially bisphosphonates) have significant immediate,
as well as rare, but serious long-term side-effects, making for poor compliance and refusal to initiate therapy.
Given this array of issues associated with late drug intervention, this project will investigate whether “a stich in
time, saves nine”, by examining if early prophylaxis using anti-catabolic drugs, anabolic drugs and a non-
pharmacological nutritional supplement, to prevent bone loss from occurring early in the etiology of the disease,
is more effective at preventing bone fracture than late therapy after bone has already been denuded and
regeneration is more difficult. We will study two maladies associated with increased fracture incidence and that
disproportionally affect Veterans. 1. Postmenopausal Osteoporosis, the archetypal bone disease of women and
an escalating problem in the VA healthcare system given women are the most rapidly increasing demographic.
2. Immune reconstitution bone loss (IRBL) which is caused by antiretroviral therapy (ART) used to treat HIV
infection. We will test in mouse models, the hypothesis that short-term intervention to preserve bone mass during
the early course of the disease, is superior to the traditional standard of care approach of withholding
interventions until the skeleton has been seriously denuded, before intervening with pharmacologic approaches
that are inherently inefficient at rejuvenating lost bone, and at best delay rather than prevent fractures. We will
leverage our VA collaborative partners to synergistically expand the depth and scope of our studies and allow
us to perform extensive state-of-the-art bone phenotyping to assess bone structure, quality and fracture
resistance in the two-model system. Should our studies reveal a significant advantage for early therapy, this
would support studies future studies in humans towards a change in the standard of care for fracture prevention.
总体研究战略:确保老年退伍军人在尽可能少的肌肉骨骼下保持活跃和活动
尽可能疼痛,预防骨质疏松症和促进及时骨再生的新方法
骨折后是必要的。这项合作研究汇集了一组退伍军人管理局的调查人员
以不同的视角、见解、模型和技术,协同解决重大临床问题
这会导致退伍军人的高发病率和死亡率,导致骨折。每个项目的总体研究策略
综合项目是使用一种疾病的临床前模型,这种疾病要么削弱骨骼,要么推迟骨骼修复,以
探索利用或增强甲状旁腺激素(PTH)促进骨形成的新方法,
并对骨骼疾病和治疗效果进行统一、严格的评估。已经被低估了
如果治疗不当,骨质疏松症可能会增加退伍军人医院治疗的脆性骨折的数量
没有新的早期发现工具和新的治疗策略来规避罕见但毁灭性的
目前抑制骨质流失的治疗方法的副作用。解决这一未得到满足的临床需求,总体目标是
确定治疗策略以改善退伍军人的骨健康,并增强退伍军人的骨合成代谢
PTH信令。这项合作将解决这个最重要的假设:健康问题不成比例
影响退伍军人激活信号通路,增加骨吸收,抑制骨形成,或
阻碍骨折骨痂中软骨向骨的转变,从而改善临床治疗
骨质疏松的关键在于了解这些健康问题是如何损害骨骼健康的。
项目研究策略:预防骨折的传统临床护理标准,是筛查
骨质疏松症在疾病病程的晚期,在骨质被剥离和骨折迫在眉睫之后,在
求助于抗骨质疏松症药物疗法。然而,这样的疗法在再生丢失方面效率低下。
骨骼和骨骼质量是承重强度的一个重要方面,但往往仍然不足。因此,临床上
护理标准往往是不够的,许多患者最终会继续骨折,无论
接受治疗的机会。使问题雪上加霜的是,抗吸收药(尤其是双膦酸盐)有显著的立竿见影的效果,
以及罕见但严重的长期副作用,导致依从性差,拒绝开始治疗。
考虑到这一系列与晚期药物干预相关的问题,该项目将调查
时间,节省9“,通过检查早期预防是否使用抗分解代谢药物,合成代谢药物和非
药理营养补充剂,以防止在疾病病因早期发生骨丢失,
在预防骨折方面比晚期治疗更有效,因为骨已经剥离和
再生则更加困难。我们将研究与骨折发病率增加相关的两种疾病
不成比例地影响退伍军人。1.绝经后骨质疏松症--妇女的典型骨病
鉴于女性是增长最快的人群,退伍军人医疗保健系统中不断升级的问题。
2.用于治疗HIV的抗逆转录病毒疗法(ART)引起的免疫重建骨丢失(IRBL)
感染。我们将在小鼠模型中测试这一假说,即短期干预以保护骨量在
疾病的早期病程,优于传统的扣留标准的护理方法
干预直到骨骼被严重剥离,然后再用药理学方法进行干预
这在修复丢失的骨骼方面天生效率低下,充其量只能延缓而不是防止骨折。我们会
利用我们的退伍军人管理局协作合作伙伴协同扩展我们研究的深度和范围,并允许
美国将进行广泛的最先进的骨骼表型鉴定,以评估骨骼结构、质量和骨折
双模型系统中的阻力。如果我们的研究揭示了早期治疗的显著优势,这一点
将支持未来在人类身上进行的研究,以改变预防骨折的护理标准。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mervyn Neale Weitzmann其他文献
Mervyn Neale Weitzmann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mervyn Neale Weitzmann', 18)}}的其他基金
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
-- - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
-- - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant